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Background: Ubiquitination plays critical roles in many cellular processes.
Results: The Entamoeba histolytica ubiquitin activating, conjugating, and ligating enzymes interact and transfer ubiquitin.
Conclusion: E. histolytica possesses a functional ubiquitination cascade with key differences from mammalian homologs.
Significance: The E. histolytica ubiquitin-proteasome pathwaymay provide therapeutic targets for amoebic colitis and amoebiasis.
Ubiquitination is important for numerous cellular processes
in most eukaryotic organisms, including cellular proliferation,
development, and protein turnover by the proteasome. The
intestinal parasite Entamoeba histolytica harbors an extensive
ubiquitin-proteasome system.Proteasome inhibitors are known
to impair parasite proliferation and encystation, suggesting the
ubiquitin-proteasome pathway as a viable therapeutic target.
However, no functional studies of the E. histolytica ubiquitina-
tion enzymes have yet emerged. Here, we have cloned and char-
acterized multiple E. histolytica ubiquitination components,
spanning ubiquitin and its activating (E1), conjugating (E2), and
ligating (E3) enzymes. Crystal structures of EhUbiquitin reveal a
clustering of unique residues on the 1 helix surface, including an
eighth surface lysine not found in other organisms, which may
allow for a unique polyubiquitin linkage in E. histolytica. EhUbiq-
uitin isactivatedbyandformsathioesterbondwithEhUba1(E1) in
vitro, in an ATP- and magnesium-dependent fashion. EhUba1
exhibits a greater maximal initial velocity of pyrophosphate:ATP
exchange than its humanhomolog, suggesting different kinetics of
ubiquitin activation in E. histolytica. EhUba1 engages the E2
enzyme EhUbc5 through its ubiquitin-fold domain to transfer the
EhUbiquitin thioester. However, EhUbc5 has a >10-fold prefer-
ence for EhUba1Ub compared with unconjugated EhUba1. A
crystal structure of EhUbc5 allowed prediction of a noncovalent
“backside” interactionwith EhUbiquitin and E3 enzymes. EhUbc5
selectively engages EhRING1 (E3) to the exclusion of two HECT
family E3 ligases, and mutagenesis indicates a conserved mode of
E2/RING-E3 interaction in E. histolytica.
Post-translational modification by ubiquitin and ubiquitin-
likemodifiers (ULMs)3 plays critical roles in the cellular biology
of many eukaryotes (1). Isopeptide bond-mediated attachment
ofmonoubiquitin or polyubiquitin chains to specific target pro-
teins regulates processes as diverse as cell cycle progression,
development, and the immune response (2). Polyubiquitination
also serves as a primary signal for protein turnover, targeting
proteins for degradation by the 26 S proteasome (3). ULM
attachments are catalyzed by conserved enzyme cascades, with
ATP-dependent ULM activation catalyzed by E1, conjugation
by E2, and targeting of specific protein substrates by E3 ligases
(3). Ubiquitin-activating enzymes (E1s) in eukaryotes serve to
adenylate ubiquitin, consuming ATP and releasing pyrophos-
phate (PPi). Subsequently, a thioester bond is formed between
an E1 active site cysteine and the dual-glycine C terminus of the
activated ubiquitin, releasing AMP, and a second ubiquitin
molecule is also adenylated (4). The resulting E1Ub thioester
complex engages a ULM-conjugating enzyme (E2), with major
contributions to the E1/E2 interface arising from the E1 ubiq-
uitin-fold domain (UFD) (5). The thioester bond between the
ubiquitin C terminus and the E1 enzyme is transferred to a con-
served cysteine residue on the E2, resulting in a covalent E2Ub
adduct (6).E3ubiquitin-ligatingenzymescanbeclassified into two
majorgroups, containingeitherhomology to theE6APCterminus
(HECT)or really interestingnewgenerelated (RING)domains (3).
HECT family E3 enzymes possess a catalytic cysteine that accepts
the ubiquitin thioester from bound E2Ub prior to ubiquitin iso-
peptide bond formation with a lysine acceptor (7). In the case of
RING E3 enzymes, ubiquitin is directly transferred to the target
protein from E2Ub; the RINGE3 enzyme serves primarily as an
adaptor pairing ubiquitin-charged E2 enzymes with specific
E3-bound substrates (3). However, RING interactions with
E2Ub also prime the E2 for efficient ubiquitin conjugation to
acceptor lysines (8). Ubiquitinmonomers can be added directly to
surface lysines on substrate proteins, or can instead be linked into
polyubiquitin chains, utilizing any of the seven lysines on the sur-
face of ubiquitin, although some polyubiquitin linkages are more
frequently utilized than others (9).
The single-celled intestinal parasite Entamoeba histolytica is
the causative agent of amoebic colitis and systemic amoebiasis,
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with the latter characterized by cysts in liver, lungs, and brain
(10). Spread in an encysted form, E. histolytica infection is
endemic in developing countries with poor barriers between
sewage and drinking water (11). Although E. histolytica has
been the subject of research for more than 50 years, the rela-
tively recent sequencing of its genome (12) affords the oppor-
tunity for further insight into cellular machinery that may be
amenable to pharmacologic manipulation, such as the ubiqui-
tin-proteasome pathway. The cloning and characterization of
an E. histolytica ubiquitin gene (termed Ehubiquitin) high-
lighted a surprising degree of sequence divergence from
homologs in humans and lower organisms, given the remark-
ably high degree of conservation among other species (13).
Despite its relatively dissimilar sequence, EhUbiquitin comple-
ments deletion of the polyubiquitin gene ubi4 in yeast, suggest-
ing conserved functions in E. histolytica (14). More recent
bioinformatic analyses of the E. histolytica genome revealed an
extensive family of putative ubiquitin activating, conjugating,
and ligating enzymes, as well as parallel systems for other ubiq-
uitin-like modifiers (15). However, functional studies of this
putative ubiquitinationmachinery have not yet emerged. Inter-
estingly, treatment with proteasome inhibitors impairs growth
of E. histolytica trophozoites and encystation in the related spe-
ciesEntamoeba invadens, suggesting that the ubiquitin-protea-
some pathway may be a valuable therapeutic target (16).
Altered expression of ubiquitin-proteasomal genes has also
been correlated with perturbations in virulence (e.g. Ref. 17).
Our own study of heterotrimeric G-protein signaling in E. histo-
lytica demonstrated that markers of trophozoite virulence are
enhanced or reduced upon overexpression of the G subunit,
EhG1, or a dominant-negative EhG1mutant, respectively (18).
A transcriptome analysis by RNA-seq revealed differential
expression of multiple ubiquitin-proteasome pathway-related
genes upon expression of wild-type or mutant EhG1, includ-
ing the Ehubiquitin gene itself (Table 1). In the present study,
we sought to characterize, both structurally and biochemically,
various components of the E. histolytica ubiquitination
machinery, spanning ubiquitin and its interacting E1–E3
enzymes. We hypothesize that differences revealed between
the E. histolytica components and well studied mammalian
homologsmay elucidate a potentialmeans for specific targeting
of ubiquitination within the parasitic amoeba.
EXPERIMENTAL PROCEDURES
Cloning and Protein Purification—Genomic DNA was iso-
lated from the virulentHM-1:IMSS strain of E. histolytica using
a DNeasy Blood and Tissue Kit (Qiagen). Open reading frames
of Ehubiquitin (AmoebaDB accession EHI_083410), Ehuba1
(EHI_020270), Ehubc5 (EHI_083560), Ehring1 (EHI_020100),
Ehhect1 (EHI_011530), and Ehhect2 (EHI_124600) were PCR
amplified from genomic DNA and subcloned as hexahistidine
fusions into a pET vector-based ligation-independent cloning
vector, pLIC-His, as described previously (19). PCR primer
sequences were: Ehubiquitin, 5-ATGCAAATATTTGTTAA-










and purified as recombinant proteins included the ubiquitin-fold
domain of EhUba1 (amino acids 882–984), EhRING1 (amino
acids 1–246), EhHECT1 HECT domain (amino acids 277–660),
and EhHECT2 HECT domain (amino acids 370–750). Point
mutations to EhUbc5 were made using PCR and the overlap
extensionmethod (20).
Recombinant human Uba1, derived from insect cells, was
purchased fromBoston Biochem.Ubiquitin from bovine eryth-
TABLE 1
Ubiquitin and proteasome system genes differentially transcribed in E. histolytica trophozoites expressing EhG1 or the dominant-negative
EhG1S37C







Hypothetical (RING finger domain) EHI_104520 1.9 (0.004)
Ubiquitin-activating enzyme EHI_004850 1.7 (0.013)
Zinc finger protein (RING-type) EHI_165120 1.8 (0.004)
Ulp1 protease family, C-terminal catalytic EHI_138530 2.2 (0.002)
F-box domain containing protein EHI_103710 1.9 (0.007)
26 S Protease regulatory subunit EHI_185410 1.8 (0.011)
RING zinc finger protein EHI_023310 2.1 (0.008)
Hypothetical (UBX domain) EHI_027910 2.5 ( 0.001)
Proteasome subunit  type 3 EHI_098060 2.0 (0.007)
Zinc finger protein (RING-type) EHI_130650 1.9 (0.004)
RING zinc finger protein EHI_161980 2.1 ( 0.001)
Zinc finger, RING-type EHI_159840 2.3 ( 0.001)
Proteasome subunit  type 2-A EHI_052140 1.7 (0.019)
WWE domain EHI_069610 1.7 ( 0.001)
Ubiquitin EHI_083410 2.2 ( 0.001)
Zinc finger, RING-type EHI_110790 2.3 ( 0.001)
Ubiquitin-conjugating enzyme E2 EHI_131530 2.0 ( 0.001)
Ubiquitin-conjugating enzyme E2 EHI_135460 1.8 (0.009)
26 S Protease regulatory subunit EHI_177320 1.9 ( 0.001)
19 S Cap proteasome S2 subunit EHI_198010 3.6 ( 0.001)
26 S Protease regulatory subunit EHI_053020 2.2 (0.020)
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rocytes was purchased from Sigma. Because the sequences of
bovineandhumanubiquitinare identical, theprotein is referred to
as human ubiquitin throughout the study, for clarity. For each of
the E. histolytica components, BL21 Escherichia coli were grown
to anA600 nm of 0.8 at 37 °C and expressionwas induced with 500
M isopropyl -D-thiogalactopyranoside for 14–16 h at 20 °C.
Pelleted bacterial cells were resuspended in N1 buffer contain-
ing 30 mMHEPES, pH 8.0, 250 mMNaCl, and 30 mM imidazole
and lysed by high-pressure homogenization with an Emulsiflex
(Avestin;Ottawa, Canada). Cellular lysateswere cleared by cen-
trifugation at 100,000  g for 1 h at 4 °C, and the supernatant
was applied to a nickel-nitrilotriacetic acid (NTA) FPLC col-
umn (GE Healthcare), washed extensively with N1, and eluted
in N1 buffer with 300 mM imidzaole. For proteins used in bio-
chemical experiments, eluted protein was pooled and resolved
using a size exclusion column (HiLoad 16/60 Superdex 200, GE
Healthcare) in S200 buffer containing 50 mM HEPES, pH 7.5,
and 100 mM NaCl (5 mM ZnCl2 was included in the case of
EhRING1 purification). For proteins used in crystallographic
studies, protein eluted from the NTA column was pooled and
dialyzed into imidazole-free N1 supplemented with 5 mMDTT
overnight at 4 °C in the presence of His6-tobacco etch virus
protease to cleave theN-terminal affinity tag. The dialysate was
then passed over a secondNTAcolumn to remove tobacco etch
virus protease and uncleaved protein, followed by resolution by
size exclusion in S200 buffer. All proteins except EhUba1 were
concentrated to 0.25–2mMand snap frozen in a dry ice/ethanol
bath for storage at 80 °C. EhUba1 was found to precipitate
upon freeze/thaw, but could be stably maintained at 4 °C for at
least 2 weeks. Protein concentration was determined by A280
nm measurements upon denaturation in 8 M guanidine hydro-
chloride, based on predicted extinction coefficients for each
protein using Expasy.
Crystallization and Structure Determinations of EhUbiquitin
and EhUbc5—Crystals of EhUbiquitin were obtained by vapor
diffusion from hanging drops at 18 °C in two different crystal
forms. EhUbiquitin crystal form 1 was obtained by mixing
EhUbiquitin at 17mg/ml (1:1)with crystallization solution con-
taining 25% (w/v) PEG 3350 and 100 mM citric acid, pH 3.5. A
single crystal grew to500 400 400mover 5 days, exhib-
iting the symmetry of space group P3221 (a  b  49.8 Å, c 
63.8 Å,     90°,   120°) and containing onemonomer in
the asymmetric unit. For the second crystal form, EhUbiquitin
at 13mg/ml in S200 bufferwasmixed 1:1with (and equilibrated
against) crystallization solution containing 22% (w/v) PEG
3350, 200mMLiSO4, and 100mMBisTris, pH 5.5. Crystals grew
to 200  100  100 mover 3 days, exhibiting the symmetry
of space group P212121 (a 38.6 Å, b 49.9 Å, c 76.8 Å,  
    90°) and containing two monomers in the asymmetric
unit. For data collection at 100 K, crystals were serially trans-
ferred for 1 min into crystallization solution supplemented
with 30% (v/v) glycerol in 10% increments and plunged into
liquid nitrogen. Native data sets were collected at the GM/CA-
CAT 23-ID-B beamline at the Advanced Photon Source
(Argonne National Laboratory). Data were processed using
HKL2000 (21). The crystal structuremodel of human ubiquitin
(PDB code 1UBQ) was used as a molecular replacement search
model using PHENIX AutoMR (22). Refinement was carried
out using phenix.refine (22), interspersed with manual revi-
sions of the model using the program Coot (23). Refinement
consisted of conjugate-gradient minimization and calculation
of individual anisotropic displacement and translation/libra-
tion/screw parameters (24). The current model of crystal form 1
contains one EhUbiquitin monomer; residues 7–10 and 73–77
could not be located in the electron density. Ramachandran plot
analysis indicated 100% favored residues. The current model of
crystal form 2 contains two EhUbiquitin monomers; residues
75–77 of chain A and 74–77 of chain B could not be accurately
modeled in the electrondensity. Ramachandranplot analysis indi-
cated 98.6% favored, 1.4% allowed, and 0% disallowed residues.
Crystals of EhUbc5 were obtained by vapor diffusion from
hanging drops at 18 °C. EhUbc5 at 8 mg/ml in S200 buffer was
mixed 1:1 with (and equilibrated against) crystallization solu-
tion containing 100 mM Tris, pH 7.5, 14% (w/v) polyvinylpyr-
rolidone K15, and 500 M CoCl2. Hexagonal crystals grew to
400 300 200mover 5 days and exhibited the symmetry
of space group P212121 (a 47.0 Å, b 49.6 Å, c 63.5 Å,  
    90°) with one monomer in the asymmetric unit. For
data collection at 100 K, crystals were transferred for 1 min
into crystallization solution supplemented with 25% glycerol
andplunged into liquid nitrogen.Anative data setwas collected
at the SER-CAT 22BM beamline at the Advanced Photon
Source (Argonne National Laboratory). Data processing and
refinement were carried out similarly to EhUbiquitin, as men-
tioned above. A molecular replacement solution was obtained
using the crystal structuremodel of humanUbcH5b (PDB code
2ESK), modified to exclude water. The current model contains
one EhUbc5monomer with a cobalt ion coordinated by surface
residues and by a monomer from the neighboring asymmetric
unit. All EhUbc5 residues could be located in the electron den-
sity. Ramachandran plot analysis indicated 97.3% favored, 2.7%
allowed, and 0% disallowed residues.
In Vitro Ubiquitin Transfer Assay—Ubiquitin transfer exper-
iments were conducted essentially as previously described for
NEDD8ylation (25), with adaptations to allow visualization of
EhUba1EhUb thioester formation. Briefly, 1 M EhUba1, 5 M
wild-type or mutant EhUbc5, and 15 M EhUbiquitin were incu-
bated 15 min at room temperature in ubiquitin transfer buffer
containing 50 mM HEPES, pH 7.5, 100 mM NaCl, 10 mM MgCl2,
and 5 mMATP. The reactions were halted by denaturation in 5
nonreducing SDS sample buffer, and 50 mM DTT was added to
specified reactions for 10min prior to protein separation by dena-
turing SDS-PAGE and staining with Coomassie Blue.
In Vitro Polyubiquitin Chain Formation Assay—Polyubiqui-
tin chain formation experiments were conducted essentially as
previously described (26). 50 nM EhUba1, 1 M EhUbc5, 8 M
N-terminal FLAG epitope-tagged EhUbiquitin, and 10 M
EhRING1 were incubated at 37 °C for 45 min in reaction buffer
containing 50mMHEPES, pH 7.5, 100mMNaCl, 10mMMgCl2,
and 5 mM ATP. Reactions were halted by denaturation in 5
reducing SDS sample buffer, and 50 mM DTT was added to all
reactions 10 min prior to protein separation by SDS-PAGE.
Proteins were transferred to a nitrocellulose membrane and
probed with anti-FLAG (M2 monoclonal; Sigma).
PPi:ATP Radioisotope Exchange Assay—Isotope exchange
assays were conducted as previously described (4). All assays
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were performed at 37 °C and contained 6 nM E1 ubiquitin-acti-
vating enzyme, 1 M ubiquitin protein, 100 M AMP, 10 mM
MgCl2, 100 M nonradioactive pyrophosphate (PPi), and vari-
able ATP concentrations. Reactions were initiated by addition
of the E1 enzyme. Concentrations of EhUba1 and human Uba1
were determined by the Bradford method. Incubation times
were 15 min and within the linear portion of the progress
curve (prior to approaching equilibrium). Incorporation of
32PPi into ATP was determined by adsorbing the ATP to acti-
vated charcoal. Reactionswere quenchedwith 5% (w/v) trichlo-
roacetic acid (TCA) containing 4 mM nonradioactive PPi,
mixed with a 10% (w/v) slurry of charcoal in 2% TCA, pelleted
by centrifugation, and washed three times with 2% TCA. Char-
coal-bound radioactivity was quantified by Cherenkov radia-
tion. Background radiation from control reactions lacking E1
was subtracted, and no significant exchange was observed in
the absence of E1, ubiquitin, or ATP. All assays were performed
in duplicate, and error bars represent S.E. from three indepen-
dent experiments. Data were fit by linear regression using
GraphPad Prism version 5.0. Approximate Km and Vmax values
were derived from a Lineweaver-Burk plot, where the y inter-
cept  1/Vmax and the x intercept  1/Km.
Surface Plasmon Resonance (SPR) Assays—SPR-based mea-
surements of protein-protein interactions were performed on a
Biacore 3000 (GE Healthcare), essentially as described previously
(19). Briefly, purified His6-EhUbc5 and His6-EhUbc5(F62A) pro-
teins were separately immobilized on an NTA biosensor chip
using covalent capture coupling (27). EhUbiquitin, EhUba1, or
E3 ligase proteins were injected in 30-l volumes at increasing
concentrations. For binding experiments with EhUba1-EhUb,
20 M EhUba1 and 50 M EhUbiquitin were incubated 20 min
at 30 °C in buffer containing 50 mM HEPES, pH 7.5, 100 mM
NaCl, 1 mM ATP, and 10 mM MgCl2 to allow for ubiquitin
activation and thioester formation. EhUba1-EhUbwas injected
in 30 l volumes using the KINJECT command with a 300-s
dissociation time. Each EhUba1-EhUb injection was followed
by a 10-l injection of 50 mMDTT to detach thioester-coupled
EhUbiquitin from the EhUbc5 surface. Experiments were per-
formed in running buffer containing 50mMHEPES, pH 7.4, 150
mMNaCl, 0.05%Nonidet P-40 alternative (Calbiochem), 50M
EDTA, and 1 mM MgCl2. Background changes in refractive
index upon injection of samples was subtracted from all curves
using BIAevaluation software version 3.0 (GE Healthcare).
Equilibrium binding analyses were conducted as previously
described (28) using GraphPad Prism version 5.0 to determine
binding affinities.
RESULTS
Structural Features of a Divergent Ubiquitin from E.
histolytica—To give spatial context to the variant residues
within E. histolytica ubiquitin (13) and their effects, if any, on
the overall structure, we crystallized EhUbiquitin and deter-
mined its structure in two crystal forms. Under the first set of
conditions, a single crystal was obtained that yielded diffraction
data extending to 1.35-Å resolution. Although the diffraction
data were of otherwise high quality (Table 2), detector overload
resulted in exclusion of a significant fraction of low-resolution
data during processing. Incomplete low-resolution data were
manifested as unusually high R-factors and average B-factors
during refinement (Table 2); however, the electron density was
of good quality (Fig. 1B), with clear electron density obtained
for the divergent residues of EhUbiquitin upon phasing by
molecular replacement with human ubiquitin (PDB code
1UBQ). We also obtained EhUbiquitin crystals under a second
TABLE 2
Data collection and refinement statistics for EhUbiquitin and EhUbc5
EhUbiquitin (#1) EhUbiquitin (#2) EhUbc5
PDB accession code 4GU2 4GSW 4GPR
Data collection
Space group P3221 P212121 P212121
Cell dimensions
a, b, c (Å) 49.80, 49.80, 63.83 38.61, 49.87, 76.82 46.97, 49.58, 63.46
, ,  (°) 90.0, 90.0, 120.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Wavelength (Å) 1.000 1.000 1.000
Resolution (Å) 25.7–1.35 (1.36–1.35)a 40.0–2.15 (2.17–2.15)a 50.0–1.60 (1.62–1.60)a
No. unique reflections 20493 (486) 8430 (210) 19998 (426)
Rmerge (%) 4.3 (55.7)b 8.5 (27.9)b 4.4 (30.9)b
I/I 100 (6.9) 32.8 (3.1) 45.6 (2.8)
Completeness (%) 99.0 (100.0) 97.5 (96.8) 99.2 (87.3)
Redundancy 19.2 (17.9) 3.5 (3.3) 8.2 (3.7)
Wilson B-factor (Å2) 18.9 31.9 17.1
Refinement
Resolution (Å) 25.6–1.35 (1.42–1.35) 34.5–2.15 (2.28–2.15) 39.0–1.60 (1.64–1.60)
No. reflections 20454 (2718) 8379 (1154) 19950 (1148)
Rwork/Rfree (%) 22.0/27.4 (22.8/31.3) 20.9/27.1 (26.6/35.0) 17.6/20.5 (20.6/26.0)
No. atoms
Protein 1157 1171 1195
Ligand/ion 1
Water 66 44 179
Average B-factors (Å2)
Protein 55.2 41.5 15.0
Ligand/ion 8.1
Water 58.5 41.9 27.2
Root mean square deviations
Bond lengths (Å) 0.015 0.014 0.014
Bond angles (°) 1.642 1.493 1.504
a Values in parentheses are for highest-resolution shell.
b All data were collected from a single crystal.
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condition, and a structure was determined using diffraction
data to 2.15 Å (Table 2 and Fig. 1C). The data collection and
refinement statistics corresponding to the second EhUbiquitin
crystal form were near the mean of other deposited structures
of similar resolution (22). Although the structures derived from
both diffraction data sets were essentially identical, the second
crystal form was utilized for further analyses due to the unusu-
ally high R-factors of crystal form 1.
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TheC trace of EhUbiquitin is highly similar to human ubiq-
uitin (root mean square deviation 0.78 Å; Fig. 1A). This finding
is consistent with the protein core residues being identical
between the two homologs (13), with the exception of position
26, which exhibits a subtle variation of isoleucine in E. histo-
lytica compared with the conserved valine in a broad diversity
of other species (Fig. 1D). Mapping the variant EhUbiquitin
residues comparedwith its humanhomolog revealed clustering
of divergent residues on a single surface, dominated by the 1
helix and including proximal portions of the 2-1 and 3-4
loops (Fig. 1A). Notably, one of the residues unique to E. histo-
lytica (Fig. 1D) is an extra surface lysine (Lys-54). Because each
FIGURE 2. The divergent EhUbiquitin surface is not frequently utilized by structurally elucidated ubiquitin-binding proteins. A, the nonidentical
residues of EhUbiquitin cluster onto a single surface dominated by the first -helix. This ubiquitin surface is not utilized by many of the best-studied and
structurally characterized ubiquitin binding partners. EhUbiquitin (gray) was superimposed on structural models of ULM homologs in complex with ULM-
interacting proteins. Ubiquitin thioester formation with conjugating E2 enzymes and a HECT family E3 ligase are represented by UbcH5B (PDB code 3A33) (6)
and the Nedd4 HECT domain (PDB code 2XBB) (40), respectively. Ubiquitin interaction with de-ubiquitinating (DUB) enzymes is illustrated by the SAGA DUB
complex (PDB code 3MHS) (41). A ubiquitin interacting motif (UIM) protein is also exemplified by RAP80 (PDB code 3A1Q) (42). B, the domain structure of yeast
Uba1 is drawn and colored as in Ref. 30. The interaction of EhUbiquitin with E1 enzymes was modeled by superposition of EhUbiquitin with yeast Uba1Ub
(PDB code 3CMM). The divergent residues of EhUbiquitin (colored yellow and orange as in Fig. 1) are not predicted to alter interaction with E1 enzymes. IAD
indicates the inactive adenylation domain, FCCH is the first catalytic cysteine half-domain, 4HB is the four-helix bundle domain, AAD is the active adenylation
domain, SCCH is the second catalytic cysteine half-domain, and UFD is the ubiquitin-fold domain. C, E1 enzyme sequence similarity and identity were compared
across species. EhUba1 is most similar to that of the slime mold D. discoideum.
FIGURE 1. Sequence variations in EhUbiquitin cluster on a single surface. A, the crystal structure of EhUbiquitin (gray) is superimposed with human
ubiquitin (wheat; PDB code 1UBQ), highlighting the similarities of their backbone structures. Sequence and structural alignments were used to identify
conservative (yellow) and nonsimilar (orange) amino acid differences between the E. histolytica and human homologs. The nonidentical residues of the
EhUbiquitin cluster onto a single surface dominated by the first -helix. EhUbiquitin possesses an additional surface lysine (Lys-54) that may allow for unique
polyubiquitin linkage in E. histolytica. B, diffraction data for EhUbiquitin crystal form 1 extended to 1.35-Å resolution. Despite low-resolution incompleteness,
the 2Fo  Fc electron density map contoured to   3.0 was of good quality. Red spheres represent ordered water molecules. C, diffraction data from the
EhUbiquitin crystal form 2 were of high quality, given a lower resolution limit of 2.15 Å. The 2Fo  Fc electron density map is contoured to   3.0. D, the protein
sequence of EhUbiquitin was aligned to ubiquitin molecules from other species. EhUbiquitin shows the highest degree of sequence divergence, with 7
nonidentical residues compared with human ubiquitin. The predicted sequence of EhUbiquitin also includes a C-terminal tyrosine that may be cleaved in E.
histolytica trophozoites to expose a conserved C-terminal Gly-Gly motif. D.m. indicates Drosophila melanogaster; S.c. is S. cerevisiae, H.s. is Homo sapiens; D.d. is
Dictyostelium discoideum; and M.m. is Mus musculus.
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surface lysine on mammalian ubiquitin can be utilized for
polyubiquitin chain formation (9), it may be that E. histolytica
possesses a unique Lys-54 linkage polyubiquitination pattern.
To identify potential interactions that may involve the diver-
gent EhUbiquitin surface, we superimposed the EhUbiquitin
structure on a number of ubiquitin complex structures avail-
able in the RCSB database. Most of the surface of ubiquitin is
utilized by one or more ubiquitin-binding proteins; however,
the well characterized interactions with E2 conjugating
enzymes (e.g. UbcH5), HECT family E3 ligases, deubiquitinat-
ing enzymes (e.g. the SAGA complex), and ubiquitin-interact-
ing motifs (e.g. RAP80) are not predicted to form significant
interactions with the unique ubiquitin residues of E. histolytica
(Fig. 2A). Thus, at this time, we do not predict that the sequence
variation seen in EhUbiquitin will significantly affect its inter-
actions with similar ubiquitin-binding proteins encoded by the
E. histolytica genome. The distinct EhUbiquitin surface may be
utilized for other interactions unique toE. histolytica. However,
no specific function of the divergent EhUbiquitin surface can be
ascribed at this time.
EhUbiquitin Is Activated by the E1 Enzyme EhUba1—The E.
histolytica genome encodes a single predicted ubiquitin-acti-
vating E1 enzyme, as well as predicted activating enzymes for
Nedd8, SUMO, and other ubiquitin-like modifiers (15). The
putative ubiquitin-activating enzyme EhUba1 (AmoebaDB
accession EHI_020270) was cloned from genomic DNA,
expressed, and purified from E. coli. EhUba1 possesses a pre-
dicted domain structure similar to Saccharomyces cerevisiae
Uba1 and other eukaryotic E1s (not shown). The sequence of
EhUba1 was most similar to that of the slime mold D. discoi-
deum, followed by S. cerevisiae, when compared with a broad
spectrum of E1 enzyme sequences from different species (Fig.
FIGURE 3. The ubiquitin-activating enzyme EhUba1 catalyzes EhUbiquitin thioester formation and transfer to the E2 enzyme EhUbc5. A, recombinant
EhUba1 derived from E. coli forms a thioester bond with EhUbiquitin in an ATP- and magnesium-dependent fashion, as illustrated by SDS-PAGE and Coomassie
Blue staining under nonreducing conditions. Activated EhUbiquitin is seen to be transferred to the ubiquitin-conjugating enzyme EhUbc5. Each of the covalent
interactions detected was sensitive to 50 mM DTT reducing agent. The loss-of-E3-binding mutant EhUbc5(F62A) did not significantly affect ubiquitin thioester
formation. B, EhUba1 and EhUbc5 were sufficient to catalyze polyubiquitin chain formation in the presence of ATP and magnesium, as detected by SDS-PAGE
and Western blotting (IB) under reducing conditions. EhUba1 and EhUbc5 were seen to efficiently promote formation of chains up to four ubiquitin molecules
under these conditions, and addition of EhRING1 had modest effects. C, PPi:ATP radioisotope exchange was utilized to compare in vitro ubiquitin activation by
EhUba1 and human Uba1 in the presence of 6 nM E1 enzyme, 1 M ubiquitin, 1 mM ATP, 100 M AMP, and 100 M nonradioactive PPi. Under these conditions
EhUba1 exhibited a statistically significant 3.5-fold increase in isotope exchange rate compared with its human homolog (460  33 (95% C.I.) versus 132 
46 (95% C.I.) pmol/min). The observed difference in ubiquitin activation kinetics is apparently intrinsic to the E1 enzyme, because the isotope exchange rate was
independent of the ubiquitin species utilized. These data represent average values of triplicate experiments with mean  S.E. * indicates a statistically
significant difference between EhUba1 and human Uba1 determined by Student’s t test. D, the dependence of human Uba1- and EhUba1-mediated isotope
exchange on ATP was assessed under identical conditions as panel C, excepting ATP concentration. A Lineweaver-Burk plot allowed estimation of Km and Vmax
values describing E1 activity with respect to ATP. Under these conditions, the apparent Km and Vmax values were 45 M and 459 pmol/min (95% C.I. 392–552
pmol/min) for the E. histolytica components and 50 M and 115 pmol/min (95% C.I. 93–152 pmol/min) for the human components, with respect to ATP. Each
initial velocity measurement was conducted in duplicate, and the displayed results are representative of two independent experiments.
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2C). To determine whether EhUba1 was capable of activating
EhUbiquitin, we examined in vitro ubiquitin transfer with puri-
fied components. EhUba1 was seen to form a typical thioester
bond with EhUbiquitin that was sensitive to reduction by DTT
(Fig. 3A).MagnesiumandATPwere required for ubiquitin acti-
vation and thioester bond formation, suggesting a conserved
mechanism of ubiquitin activation in E. histolytica. A number
of mammalian E2 enzymes, together with an E1, are capable of
catalyzing formation of isopeptide-linked polyubiquitin chains
(29). In vitro polyubiquitination experiments revealed that
EhUbc5, together with EhUba1 could efficiently promote for-
mation of EhUbiquitin chains up to four molecules in length
(Fig. 3B). Polyubiquitin chain formation required E2 enzyme, as
well as the EhUba1 cofactors of magnesium and ATP.
We next sought to compare the activities of ubiquitin acti-
vating enzymes fromE. histolytica and humans. To quantify the
kinetics of enzyme-dependent incorporation of pyrophosphate
(PPi) into ATP, an in vitro radioactive 32PPi:ATP isotope
exchange assay was employed as described previously (4). In
the presence of 1 M ubiquitin protein, 100 M AMP, 10 mM
MgCl2, and 100 M nonradioactive PPi, the initial rate of PPi:
ATP exchange catalyzed by human Uba1 was 132 pmol/min
(linear regression 95% confidence interval (C.I.) 88–176 pmol/
min) (Fig. 3C), in good agreement with previousmeasurements
FIGURE 4. EhUba1 interacts directly with EhUbc5 through its ubiquitin-fold domain, and affinity is enhanced by the presence of activated EhUbiqui-
tin. A, the protein sequence of EhUbc5 was aligned to its closest homologs in yeast and humans, as well as human Ubc12. The secondary structure elements
reflect the crystal structure of EhUbc5. Residues involved in interaction with E2 binding partners were derived from previously published structures (PDB IDs
in parentheses). The majority of predicted interaction residues are conserved in EhUbc5. B, surface plasmon resonance was utilized to measure direct binding
of either unconjugated EhUba1 or its isolated UFD to immobilized EhUbc5. EhUba1 binds EhUbc5 with low affinity in the absence of activated EhUbiquitin, and
the UFD of EhUba1 is sufficient for binding. C, EhUba1 was allowed to form covalent linkage with activated EhUbiquitin prior to injection over immobilized
EhUbc5. Residual resonance following injection of EhUba1-EhUb was sensitive to the reducing agent DTT, likely indicating thioester transfer of EhUbiquitin to
the immobilized EhUbc5. D, the apparent affinity of EhUba1EhUb for EhUbc5 was significantly higher than that of unconjugated EhUba1 (panel B). The
apparent KD value of 12 M is likely overestimated because less than 100% of the injected EhUba1 is expect to be conjugated to EhUbiquitin (Fig. 3) and
equilibrium of binding could not be reached under these experimental conditions (panel C). The loss of E3-binding mutant EhUbc5(F62A) did not significantly
affect affinity for EhUba1EhUb.
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under similar conditions (4). EhUba1, in contrast, exhibited a
significantly faster initial isotope exchange velocity of 460
pmol/min (95% C.I. 428–493 pmol/min), under identical con-
ditions. The 3.5-fold greater velocity of exchange for EhUba1
comparedwith humanUba1 is intrinsic to the E1 enzyme, given
that the respective exchange rates in the presence of either
human orE. histolytica ubiquitin substrateswere indistinguish-
able (Fig. 3C). A superimposition of EhUbiquitinwith the struc-
tural model of S. cerevisiae Uba1Ub suggests that the diver-
gent ubiquitin surface in E. histolytica is not utilized in the
E1/ubiquitin interface (Fig. 2B), consistent with similar kinetics
of the E1 enzymes in activating either the human or E. histo-
lytica ubiquitin substrate. Residues that contact ATP in other
E1 enzymes (e.g. Ref. 30), such as the GXGXXGCE motif, are
well conserved in EhUba1 (not shown).ALineweaver-Burk plot
was constructed based upon PPi:ATP exchange experiments
with varying ATP concentrations, allowing estimation of Km
and Vmax with respect to the ATP substrate for both human
and E. histolytica E1 enzymes (Fig. 3D). EhUba1 exhibited
higher velocities of isotope exchange with Vmax  459 pmol/
min (95% C.I. 392–552 pmol/min), compared with its human
homolog with Vmax  115 pmol/min (95% C.I. 93–152 pmol/
min) under these conditions. However, the Km values with
respect to ATP were highly similar, being 45 and 50 M,
respectively (Fig. 3D).
EhUba1 Engages the E2 Enzyme EhUbc5 and Transfers Acti-
vated EhUbiquitin—A number of predicted E2 ubiquitin-con-
jugating enzymes have been identified within the E. histolytica
genome, although none has been functionally assessed (15).We
cloned a subset of candidate E2s from the E. histolytica genome
and attempted to express and purify each of them from E. coli.
One E2 protein (Amoeba DB accession EHI_083560; Fig. 4A)
with similarity to yeast Ubc4 and Ubc5 (termed EhUbc5) was
highly expressed and thus selected for further study. Surface
plasmon resonance was performed with immobilized EhUbc5,
indicating a low affinity interaction with non-ubiquitin-associ-
FIGURE 5. The crystal structure of EhUbc5 is highly similar to human UbcH5B despite sequence divergence. A, the crystal structure of EhUbc5 (gray) is
superimposed on its closest human homolog, UbcH5B (wheat, PDB code 2ESK) (43). Sequence and structural alignment was used to identify conservative
(yellow) and nonsimilar (orange) amino acid differences between the E. histolytica and human homologs. B, a representative 2Fo  Fc electron density map of
the EhUbc5 hydrophobic core, contoured to   2.5, was rendered using PyMol. C, cobalt (cyan sphere) was required for crystallization and found incorporated
in the crystal lattice at an interface between symmetry-related EhUbc5 molecules. Cobalt ion (cyan sphere) is coordinated by two histidines and an aspartic acid
from one EhUbc5 molecule (yellow), a glutamine from the adjacent EhUbc5 molecule (green), and a water molecule. Each of the six apparent coordinating
groups is 2.1–2.2 Å from the cobalt ion. The 2Fo  Fc electron density map is contoured to   3.5.
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ated EhUba1 (Fig. 4B). A KD value for the EhUba1/EhUbc5
interaction could not be precisely quantified by equilibrium
binding analyses due to the protein concentration limitations of
our assay, but was greater than 150 M. The isolated ubiquitin-
fold domain (UFD) of EhUba1 (amino acids 882–984) exhibited
a similar apparent affinity for EhUbc5, indicating its sufficiency
for binding the E2 (Fig. 4B). In similar SPR experiments,
EhUba1 was first allowed to activate EhUbiquitin and form an
EhUba1Ub thioester complex (under conditions similar to
Fig. 3A) prior to injection over an EhUbc5 surface. Following
dissociation of EhUba1Ub, persistent residual resonance was
observed (Fig. 4C), suggesting that some activated ubiquitin
may be transferred covalently to the EhUbc5-laden surface.
Indeed, the residual resonance due to the apparent thioester-
coupled EhUbiquitin could be rapidly eliminated by injection of
the reducing agentDTT (Fig. 4C). An equilibriumbinding anal-
ysis suggested at least a 10-fold greater affinity of EhUbc5 for
EhUba1Ub than for unconjugated EhUba1 (Fig. 4D). Notably,
the apparent affinity of EhUbc5 for EhUba1EhUb (KD  12
M) is likely underestimated by this approach, given that satu-
ration could not be reachedwith each analyte injection (Fig. 4C)
and the reported EhUba1EhUb concentrations (Fig. 4D)
assume that 100% of the EhUba1 enzyme injected was conju-
gated to ubiquitin. However, correction of either potential
source of error would further lower the apparent EhUba1Ub/
EhUbc5 dissociation constant value, resulting in a 	10-fold
preference of EhUbc5 for EhUbiquitin-conjugated over uncon-
jugated EhUba1. Transfer of the EhUbiquitin thioester from
EhUba1 to EhUbc5 was also demonstrated by an in vitro assay
(Fig. 3A). Ubiquitin activation by EhUba1 and subsequent
transfer to the E2 enzyme was found to be dependent on the
presence of ATP andmagnesium. The EhUbc5-EhUb thioester
bond was also sensitive to the reducing agent DTT.
Structural Features of the E2 Ubiquitin-conjugating Enzyme
EhUbc5 and Its Noncovalent Interaction with EhUbiquitin—To
gain further insight into ubiquitin conjugation in E. histolytica,
EhUbc5 was crystallized and its structure determined by
molecular replacementwith diffraction data extending to 1.6-Å
resolution (Table 2). Although EhUbc5 crystallized under a
variety of conditions, the crystal form described here required a
cobalt (II) salt. A cobalt ion could be identified in the electron
density, contacting EhUbc5 molecules in adjacent asymmetric
units (Fig. 5C). The cobalt ion appears to be octahedrally coor-
dinated with two histidine and one aspartate ligand from one
FIGURE 6. EhUbc5 engages EhUbiquitin through covalent thioester and noncovalent backside interactions. A, the predicted interactions of EhUbc5 with
thioester-conjugated ubiquitin (blue) and noncovalent backside bound ubiquitin (purple) was modeled by superimposition of EhUbc5 with human
UbcH5BUb (PDB code 3A33) (6) and noncovalent UbcH5A/Ub (PDB code 3PTF) (33). The two predicted ubiquitin interfaces of EhUbc5 are relatively well
conserved, suggesting similar modes of interaction in E. histolytica. B and C, EhUbc5 interacts noncovalently with EhUbiquitin, as determined by SPR. The low
affinity of interaction is consistent with the analogous interaction between human E2 domains and human ubiquitin (2).
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EhUbc5 monomer, complemented by a glutamine from a sym-
metry-related EhUbc5 and by a water molecule. The overall
structural model of EhUbc5 is remarkably similar to human
UbcH5B (C root mean square deviation of 0.69 Å), given only
73% sequence identity and 83% similarity (Figs. 4A and 5A). As
seen in the case of EhUbiquitin, the majority of the EhUbc5
hydrophobic core is identical to human UbcH5B, whereas
divergent residues predominantly reside on the protein surface
(Fig. 5, A and B). The 4-2 and 2-3 loops are highly con-
served among E2 enzymes, including EhUbc5 (Fig. 4A), sug-
gesting a likely conserved mode of interaction with covalently
attachedubiquitin (Fig. 6A). In particular, EhUbc5Cys-85 likely
forms a thioester bond with the C terminus of activated
EhUbiquitin (Fig. 3A). E2 enzymes are also known to bind ubiq-
uitin-like modifiers in a noncovalent, “backside” interaction
thought to be important for assembly of polyubiquitin chains
(31, 32). To assess a potential noncovalent interaction between
EhUbc5 and EhUbiquitin, we predicted E2 enzyme residues
likely to be involved based on the known interaction between
humanUbcH5A and human ubiquitin (Fig. 4A) (33). The anal-
ogous residues in EhUbc5 were 62% identical and 87% simi-
lar, suggesting a potentially conserved noncovalent interac-
tion with EhUbiquitin. In support of this hypothesis,
EhUbiquitin was found to bind EhUbc5, as measured by SPR
(Fig. 6, B and C). The apparent low affinity of the EhUbc5/
EhUbiquitin interaction (KD  410  80 M) is consistent
with other monoubiquitin interactions, specifically homolo-
gous noncovalent interactions with other E2 enzymes (KD
values 100–500 M) (2, 31).
EhUbc5 Engages a RING Family E3 Ubiquitin Ligase—We
next sought to identify E3 ligases in E. histolytica thatmay part-
ner with EhUbc5 to ubiquitinate specific substrate proteins.
The E. histolytica genome encodes a large number of putative
E3 enzymes including HECT, RING, PHD, and U-box domain-
containing proteins (15). A subset of candidate E3s were cloned
from E. histolytica genomic DNA and expressed in E. coli. Of
this subset, one RING family E3 and two HECT domains could
be purified to near homogeneity in quantities suitable for bio-
chemical experiments. The RING family protein (AmoebaDB
accession EHI_020100), here termed EhRING1, contains pre-
dicted RING and zinc finger motifs according to SMART (34),
although significant sequence divergence results in relatively
high domain prediction E-values (Fig. 7B). We were unable to
identify a clear homolog for EhRING1 in either humans or
yeast. The first 246 amino acids of EhRING1 were seen to bind
EhUbc5 with a dissociation constant of 9.5  0.5 M, as deter-
mined by SPR (Fig. 7, B and C). In contrast, the HECT domains
of two putative E3 ligases, termed EhHECT1 (EHI_011530) and
EhHECT2 (EHI_124600), did not bind immobilized EhUbc5
(Fig. 7,B andC). A superimposition of EhUbc5 on crystal struc-
ture models of E2 enzymes in complex with a cIAP2 RING
domain (35) and the CHIP U-box domain (36) suggests a well
conserved EhUbc5 surface at the predicted RING family E3
binding site (Fig. 7A). To test whether EhUbc5 engages
EhRING1 in a similar fashion, we mutated the conserved phe-
nylalanine 62 to alanine, a residue predicted to contribute to
RING binding. Indeed, EhUbc5(F62A) displayed a drastically
reduced affinity for EhRING1 (Fig. 7). However, EhUbc5(F62A)
FIGURE 7. EhUbc5 exhibits a conserved mode of interaction with a RING family E3 ligase. A, the predicted interaction between EhUbc5 and RING family E3
ligases was modeled by superposition of EhUbc5 on the structural coordinates of the human UbcH5-CHIP U-box complex (PDB code 2OXQ) (36) and the
UbcH5-cIAP2 RING domain complex (PDB code 3EB6) (35). Phenylalanine 62 is highly conserved across species and contributes to the E2/RING E3 interface.
B, EhRING1 possesses an N-terminal predicted RING domain and zinc finger (ZnF) domain, as well as additional, weakly predicted RING and zinc finger domains.
Domain prediction E-values were derived using SMART (34). All biochemical experiments described in this study were conducted with EhRING1 residues 1–246.
C and D, EhUbc5 bound a putative RING family E3 ubiquitin ligase from E. histolytica with low micromolar affinity, but not two HECT family E3 ligases, as
measured by SPR. Mutation of Phe-62 drastically reduced the affinity of EhUbc5 for EhRING1, indicating a likely conserved mode of E2/E3 interaction in E.
histolytica.
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maintained its ability to form a thioester bond with activated
EhUbiquitin (Fig. 3A) and to bind EhUba1-EhUb (Fig. 4D),
indicating proper folding of the point-mutated EhUbc5 pro-
tein. EhRING1 had only modest effects, if any, on EhUbc5-
catalyzed polyubiquitin chain formation, as assessed qualita-
tively by in vitro assays (Fig. 3B).
DISCUSSION
Our experiments demonstrate the presence of a functional
ubiquitin activationandconjugationpathway inE. histolytica.The
substantial differences in the EhUbiquitin protein sequence
compared with other species cluster on a single surface, con-
structed primarily of the1 helix.Our analyses suggest that this
particular surface is not central to the structurally elucidated
ubiquitin interfaces with E1s, E2s, HECT, and RING E3s, ubiq-
uitin interactingmotifs, and deubiquitinating enzymes in other
species. However, the high degree of conservation at this sur-
face in a diverse set of other organisms suggests a likely role(s)
in ubiquitin functions. EhUbiquitin may have evolved to lack
these functions, allowing sequence drift on the 1 helix and
surrounding surface. Alternatively, EhUbiquitin may have
evolved an as yet undetermined alternative use for this surface.
The function of the 1 helix region has not yet been established
in E. histolytica; accordingly, its potential value as a therapeutic
target is unclear. Of particular interest is the presence of an
eighth surface lysine (Lys-54) unique to EhUbiquitin (arginine
in all other organisms examined) and included in the divergent
surface. Complex polyubiquitination patterns utilizing all seven
surface lysines and the N terminus of ubiquitin exist in other
species, corresponding to an array of interaction modes and
affinities for various ubiquitin binding domains (37). Thus, it is
likely that additional unique polyubiquitination patterns and
interactions arise in E. histolytica, involving the additional
exposed lysine. Further studies are necessary to determine the
prevalence of Lys-54 polyubiquitination in E. histolytica and its
potential functions.
EhUba1 appears to activate ubiquitin in a similar fashion to
its homologs in other species. However, the observed signifi-
cant difference in maximal velocity of PPi:ATP exchange com-
pared with human Uba1 suggests differences in ubiquitin acti-
vation kinetics. Additional work is needed to determine
whether ubiquitin activation by this enzyme is necessary for
parasitic virulence, and whether specific inhibition of EhUba1
is a viable therapeutic goal. Inhibitors of mammalian E1s have
been used with some success, demonstrating the feasibility of
this approach (38).
EhUbc5 exhibited a striking selectivity for EhUba1Ub
compared with unconjugated EhUba1. Because the EhUba1
UFD bound EhUbc5 with an affinity similar to that of unconju-
gated EhUba1, it appears that some portion of the EhUba1Ub
complex, in addition to the UFD, contributes to E2 binding
following ubiquitin activation. An altered EhUba1 conforma-
tion, or perhaps the EhUbiquitin molecule itself, may provide a
higher affinity surface for EhUbc5. This functionality may help
EhUbc5 recognize ubiquitin-bound E1 for efficient transfer
and/or allow for rapid release of the E1-E2 complex once ubiq-
uitin transfer has occurred. The noncovalent interaction of
EhUbiquitin with EhUbc5 suggests a likely conserved mecha-
nism for conjugating polyubiquitin chains (31). EhUbc5 was
also seen to engage a RING family E3 (EhRING1) through a
conservedmode of interaction, to the exclusion of two HECT
family E3s. This finding suggests a possible RING E3 speci-
ficity for EhUbc5; however, we cannot rule out the possibility
that EhUbc5 interacts with other, untested HECT E3 ligases,
like its yeast homologs (39). It is unclear at this time which
target proteins are ubiquitinated downstream of EhUbc5
and EhRING1.
The E. histolytica ubiquitin-proteasome pathway may pro-
vide therapeutic targets for potential treatment of amoebic coli-
tis and amoebiasis. Of particular feasibility may be a protea-
some inhibitor with selectivity for the E. histolytica protein
target, given the previously demonstrated effects of proteasome
inhibition on trophozoite proliferation and encystation (16).
Alternatively, EhUba1-specific E1 inhibition may be expected
to grossly perturb trophozoite function and viability, given the
necessity of ubiquitin activation for multiple vital cellular pro-
cesses in other eukaryotes (38).
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